The Theralux™ platform compromises a novel small molecule drug, TH9402 that has two specific properties:
- it is selectively retained in actively growing cells
- it can be activated by light to turn into a lethal compound
The light activation is accomplished by a proprietary medical device. The novel small molecule, the proprietary medical device and for each indication a specific treatment protocol together, form the basis of our photodynamic therapy (PDT) that allows the selective elimination of particular harmful cells.
The novel drug TH9402 is a non-toxic molecule that passively diffuses into all cells and collects in the mitochondria. In actively growing cells that have an inactive P-glycoprotein (Pgp) pump the drug is retained. Actively growing cells are for example cancer cells and activated immune cells.
TH9402 is inactive but once exposed to a specific wavelength of visible light it becomes activated and turns into a lethal compound for cells its retained in.
